目的观察拉西地平与瑞舒伐他汀联合治疗对原发性高血压患者血压及踝肱脉搏波传导速度（baPWV）的影响。方法选择128例原发性高血压患者进行回顾性分析，将患者按照治疗方法分入拉西地平组（66例）和联合治疗组（62例），均测量血压，并检测baPWV。拉西地平组口服拉西地平4~8 mg，每日1次，联合治疗组在服用拉西地平的基础上加服瑞舒伐他汀10 mg，每日1次，6个月后再次测量血压及baPWV。结果治疗6个月，联合治疗组收缩压（125.6±10.9）mm Hg，舒张压（78.5±7.6）mm Hg，baPWV（1398±262）mm/s，低于拉西地平组收缩压（131.4±11.8）mm Hg，舒张压（83.9±5.1）mm Hg，baPWV（1671±239）mm/s，两组比较差异有统计学意义（P＜0.05）。结论拉西地平与瑞舒伐他汀联合治疗对原发性高血压患者具有降低血压，降低baPWV，改善动脉弹性作用。%Objective To study and analyze the effect of combined treatment with lacidipine and rosuvastatin on primary hypertension and arterial elasticity. Methods 128 patients with primary hypertension were divided into the lacidipine group and the combined-treatment group,with 66 patients in lacidipine group and 62 patients in combined-treatment group. All patients received lacidipine treatment. On this basis,the combined-treatment group was given rosuvastatin. The treatment course was 6 months. The levels of blood pressure and brachial-ankle pulse wave velocity(baPWV) were compared between the two groups. Results The levels of systolic pressure,diastolic pressure and baPWV in the combined-treatment group were lower than that in the lacidipine group,(125.6±10.9) mmHg vs (131.4±11.8)mm Hg,P<0.05;(78.5±7.6)mmHg vs (82.9±5.1) mmHg,P<0.05;(1398±262) mm/s vs (1671±239)m m/s , P<0.05 respectively. Conclusion The combined treatment with lacidipine and rosuvastatin is effective and safe for primary hypertension and can improve arterial elasticity.
展开▼
